Q-omics provides the consensus-scored MIR6781 profile across patient tissues and cancer cell-line models. MIR6781 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MIR6781 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, MIR6781 RNA expression shows 6,839 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CHOL, UCEC, and UVM as cancer lineages where MIR6781 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6781 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6781 survival associations across molecular data types. MIR6781 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6781 RNA expression–survival associations across cancer types. High MIR6781 expression shows unfavorable associations in CHOL, LGG, ACC, GBM, MESO and KICH. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CHOL as the clearest survival context for MIR6781 RNA expression.
This table summarizes MIR6781 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6781. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6781 shows lower tumor expression in THCA and higher tumor expression in UCEC. The UCEC box plot shows higher MIR6781 RNA expression in tumor versus normal tissue (log2 FC = +0.505, t-test p = .020).
This table shows molecular features associated with MIR6781 in patient tissues and cancer cell lines. In patient samples, MIR6781 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
